[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrooesophageal-junction-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrooesophageal-junction-cancer":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100604555","phase-1-phase-12-study-to-evaluate-th9619-in-the-treatment-of-advanced-solid-tumors-100604555",false,"NCT07151040","Phase 1\u002F2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors","A First-in-human, Phase 1\u002F2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors","ODIN","Inclusion Criteria:\n\n* Must have given written informed consent\n* Histopathologically confirmed advanced cancer (colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer and gastric cancer (including gastroesophageal junction cancer))\n* Prior treatment with at least one line of cytotoxic systemic therapy for metastatic\u002Funresectable cancer\n* Adult patients (≥18 years of age)\n* Must be willing to comply with study procedures\n\nExclusion Criteria:\n\n• History or presence of any clinically significant disorders as judged by the Investigator.","ALL","18 Years",{"count":20,"type":21},43,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.",[28,29,30,31,32,33],"Solid Tumor","Colorectal Cancer (CRC)","Squamous Cell Carcinoma of Head and Neck","Non-Small Cell Lung Cancer (NSCLC)","Gastrooesophageal Junction Cancer","Gastric Cancer","RECRUITING","2026-01-27",{"date":37,"type":38},"2026-01-28","ACTUAL",{"date":40,"type":38},"2025-08-22",{"date":42,"type":21},"2026-12",{"name":44,"class":45},"One-carbon Therapeutics AB","INDUSTRY",4]